Mehdi Ardjmand

Mehdi Ardjmand

Auto-generated profile, based on publicly available information

Mehdi Ardjmand

Department of Chemical Engineering, South Tehran Branch, Islamic Azad University, Tehran, Iran

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

25 June 2020 in ACS Omega
Verified
Journal Article
Closed access
FJFarid Jafarihaghighi
Farid Jafarihaghighi
MAMehdi Ardjmand
Mehdi Ardjmand
MHMohammad Salar Hassani
Mohammad Salar Hassani
MMMehrdad Mirzajanzadeh
Mehrdad Mirzajanzadeh
HBHasanali Bahrami
Hasanali Bahrami

1 September 2020 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
MAMaryam Sadat Ashrafzadeh
Maryam Sadat Ashrafzadeh
AAAzim Akbarzadeh
Azim Akbarzadeh
AHAmir Heidarinasab
Amir Heidarinasab
MAMehdi Ardjmand
Mehdi Ardjmand
Background: Drug delivery systems have demonstrated promising results to cross blood–brain barrier (BBB) and deliver the loaded therapeutics to the brain tumor. This study aims to utilize the transferrin receptor (TR)-targeted liposomal cisplatin (Cispt) for transporting Cispt across the BBB and deliver Cispt to the brain tumor. Methods: Targeted pegylated liposomal cisplatin (TPL-Cispt) was synthesized using reverse phase evaporation method and thiolated OX26 monoclonal antibody. The formulation was characterized in terms of size, size distribution, zeta potential, drug encapsulation and loading efficiencies, bioactivity, drug release profile, stability and cellular uptake using dynamic light scattering, flame atomic absorption spectroscopy (AAS), ELISA, dialysis membrane, and fluorescence assay. Next, the potency of the formulation to increase the therapeutic effects of Cispt and decrease its toxicity effects was evaluated in the brain tumor-bearing rats through measuring the mean survival time (MST), blood factors and histopathological studies. Results: The results showed that TPL-Cispt with a size of 157± 8 nm and drug encapsulation efficiency of 24%± 1.22 was synthesized, that was biologically active and released Cispt in a slow-controlled manner. The formulation compared to Cispt-loaded PEGylated liposome nanoparticles (PL-Cispt) caused an increase in the cellular uptake by 1.43-fold, as well as an increase in the MST of the brain tumor-bearing rats by 1.7-fold compared to the PL-Cispt (P< 0.001). TPL-Cispt was potent enough to cause a significant decrease in Cispt toxicity effects (P< 0.001). Conclusion: Overall, the results suggest that targeting the Cispt-loaded PEGylated liposome is a promising approach to develop formulation with enhanced efficacy and reduced toxicity for the treatment of brain tumor.

1 April 2018 in Journal of Environmental Chemical Engineering
Verified
Journal Article
Closed access
HCHamidreza Chitsaz
Hamidreza Chitsaz
MNMohammad Reza Omidkhah Nasrin
Mohammad Reza Omidkhah Nasrin
BGBarat Ghobadian
Barat Ghobadian
MAMehdi Ardjmand
Mehdi Ardjmand

2 August 2019 in Artificial Cells, Nanomedicine, and Biotechnology
Verified
Journal Article
Open access
FKFatemeh Zare Kazemabadi
Fatemeh Zare Kazemabadi
AHAmir Heidarinasab
Amir Heidarinasab
AAAzim Akbarzadeh
Azim Akbarzadeh
MAMehdi Ardjmand
Mehdi Ardjmand
Introduction and objective: Lung cancer is the most common one in terms of outbreak and mortality. Since most modern treatments have many side effects, finding an effective and alternative therapy seems necessary. The present study aimed to determine the effect of PEGylated liposomal etoposide nanoparticles on the lung cancer (A-549 and Calu6 cell lines). Materials and methods: The PEGylated liposomal etoposide nanoparticles were prepared by reverse-phase evaporation method. The particle size and zeta potential of the nanoparticles were measured by Zetasizer. The nanoparticle cytotoxicity was examined by MTT method. The vesicular drug release pattern was examined by dialysis method. The amount of loaded drug and the encapsulation efficiency (EE) was also measured and calculated. Apoptosis test was performed using flow cytometry with Annexin V kit. Results: The mean particle size, size distribution, and zeta potential of PEGylated liposomal etoposide nanoparticles were 122.5 ± 4.8 nm, 0.252 ± 0.12 and −13.7 ± 0.51 mv, respectively. The etoposide release in prepared formulations was detected to be about 15.64% after 50 hr. The cytotoxic effect of etoposide nanoparticles on lung cancer A-549 and Calu6 cell lines showed more anti-tumour activity compared to the free drug used. Conclusion: The results showed that the PEGylated liposomal nanoparticles were used as a suitable nanocarrier for etoposide injection. It was also found that the drug effect on the nanodrug formulations was higher than that of the free drug.

1 July 2021 in Chemosphere
Verified
Journal Article
Closed access
SJSetare Jalali
Setare Jalali
MAMehdi Ardjmand
Mehdi Ardjmand
BRBahman Ramavandi
Bahman Ramavandi
FNFerial Nosratinia
Ferial Nosratinia